SUV2208A
/ Celest Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 03, 2026
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: Celest Therapeutics (Shanghai) Co., Ltd.
New P1 trial • Oncology • Solid Tumor • CLDN18
1 to 1
Of
1
Go to page
1